Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic Value of Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genetic insight into sick sinus syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Outcome of dialysis-requiring acute kidney injury in patients with infective endocarditis: A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognosis of myocardial infarction-related cardiogenic shock according to preadmission out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Patients with atrial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infarction (MI). Although it has been established that the efficacy of anticoagulation is superior to that of antiplatelet agents for stroke prophylaxis in AF, the optimal antithrombotic treatment remains uncertain for primary protection against MI.

OBJECTIVES: The authors investigated the incidence of first-time MI in patients with AF according to antithrombotic treatment and estimated the risk of stroke and bleeding.

METHODS: Subjects with first-time AF diagnosed from 1997 to 2012 without history of coronary artery disease were identified using Danish nationwide administrative registries. Subjects were divided into time varying exposure groups according to antithrombotic treatment. The relative risks of outcomes were estimated by Poisson regression models.

RESULTS: A total of 71,959 patients (median 75 years of age; females: 47%). At baseline, 37,539 patients (52%) were treated with vitamin K antagonist (VKA) monotherapy, 25,458 (35%) with acetylsalicylic acid (ASA) monotherapy and 8,962 (13%) with dual-therapy (VKA + ASA). The incidence of MI was 3% (n = 2,275). Relative to the VKA-treated group, the associated risk of MI was significantly higher for ASA (incidence rate ratio [IRR]: 1.54; 95% confidence interval [CI]: 1.40 to 1.68) and dual-therapy (IRR: 1.22; 95% CI: 1.06 to 1.40). The bleeding risk was significantly higher for dual-therapy (IRR: 1.93; 95% CI: 1.81 to 2.07). The risk of stroke relative to that of VKA therapy was significantly higher for both ASA (IRR: 2.00; 95% CI: 1.88 to 2.12) and dual-therapy (IRR: 1.30; 95% CI: 1.18 to 1.43).

CONCLUSIONS: VKA monotherapy in patients with AF was associated with a lower risk of first-time MI and stroke than ASA monotherapy. Combination of ASA and VKA therapy was not associated with a lower risk of MI but was associated with increased bleeding risk.

Original languageEnglish
JournalJournal of the American College of Cardiology
Volume69
Issue number24
Pages (from-to)2901-2909
Number of pages9
ISSN0735-1097
DOIs
Publication statusPublished - 20 Jun 2017

    Research areas

  • Journal Article

ID: 50610168